Oct. 23 at 3:02 AM
$RADX Brookline Capital Markets maintains Buy rating, reduces price target to
$13 due to dilution. Brookline are happy about
$LNTH increasing its stake in the company to 14.5%, a longer cash runway into 2027, and positive clinical trial updates including RAD101 (which their price target is based on)